ALN-XDH / Alnylam - LARVOL DELTA

A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout (clinicaltrials.gov) - P1/2 | N=44 | Terminated | Sponsor: Alnylam Pharmaceuticals | N=393 ➔ 44 | Trial completion date: Dec 2025 ➔ Jan 2023 | Recruiting ➔ Terminated | Trial primary completion date: May 2025 ➔ Jan 2023; The Sponsor elected not to continue with the study

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Gout • Inflammatory Arthritis • Rheumatology